WiseGuyReports.com adds “Psoriasis - Pipeline Review, H1 2016” new report to its research database. The report Spread across 771 pages with tables and figures.
The report “Psoriasis - Pipeline Review, H1 2016” provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.
Complete Report Details Available at https://www.wiseguyreports.com/reports/partnerships-licensing-investments-and-m-a-for-february-2016-in-pharmaceuticals .
Companies mentioned in this report are:
3SBio Inc., 4SC AG, Abeome Corporation, AbGenomics International, Inc., ADC Therapeutics Sarl, Addex Therapeutics Ltd, Advinus Therapeutics Ltd., Affibody AB, Ajinomoto Pharmaceuticals Co., Ltd., AlbireoPharma, Almirall, S.A., Amgen Inc., Anacor Pharmaceuticals, Inc., AnaptysBio, Inc., ApoPharma Inc., Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Athenex, Inc., Aurigene Discovery Technologies Limited, Avexxin AS, BIOCAD, Biocon Limited, BioLingus AG, BioMAS Ltd., Biomics Biotechnologies Co., Ltd., Bionomics Limited, Bionovis SA, Boehringer Ingelheim GmbH, Brickell Biotech, Inc., Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., Chipscreen Biosciences Ltd, ChironWells GmbH, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., Creabilis SA, Crescendo Biologics Limited, Curapel Limited, Delenex Therapeutics AG, Domainex Limited, Dr. August Wolff GmbH & Co. KG Arzneimittle, Effimune SAS, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Exicure, Inc., Foamix Pharmaceuticals Ltd., Forward Pharma A/S, Galectin Therapeutics, Inc., Gem Pharmaceuticals, LLC, Gene Signal International SA, Genentech, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline Plc, GliaCure Inc., GlycoMar Limited, Grupo Ferrer Internacional, S.A., Hydra Biosciences, Inc., Idera Pharmaceuticals, Inc., Immune Pharmaceuticals Inc., Immune Response BioPharma, Inc., Immungenetics AG, Innovent Biologics, Inc., Invion Limited, Jenrin Discovery, Inc., Johnson & Johnson, Kadmon Corporation, LLC, KaloBios Pharmaceuticals, Inc., Kineta, Inc., Kyowa Hakko Kirin Co., Ltd., Lead Pharma Holding B.V., Lee's Pharmaceutical Holdings Limited, LEO Pharma A/S, Lipidor AB, Lupin Limited, Mabion SA, mAbxience S.A., Maruho Co., Ltd., MediGene AG, Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Neovacs SA, Nimbus Therapeutics, LLC, NovaLead Pharma Pvt. Ltd., Novan, Inc., Novartis AG, Nuevolution AB, Oncobiologics, Inc., Panacea Biotec Limited, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phenex Pharmaceuticals AG, PinCell srl, Polichem S.A., Promius Pharma, LLC, Protalix BioTherapeutics, Inc., Prothena Corporation Plc, Provectus Biopharmaceuticals, Inc., RedHill Biopharma Ltd., Rigel Pharmaceuticals, Inc., Sandoz International GmbH, Sareum Holdings Plc, Selvita S.A., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Shulov Innovative Science Ltd., Sigmoid Pharma , imited, SignPath Pharma Inc, Soligenix, Inc., Spherium Biomed S.L., Stemline Therapeutics, Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., SWITCH Biotech LLC, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Tasly Pharmaceutical Group Co., Ltd., Telormedix SA, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Therapeutic Proteins International, LLC, Therapix Biosciences Ltd, Tolero Pharmaceuticals, Inc., UCB S.A., Valeant Pharmaceuticals International, Inc., Vitae Pharmaceuticals, Inc., vTv Therapeutics LLC, Wellstat Therapeutics Corporation, Yuhan Corporation, Ziarco Pharma Ltd.
Inquire more about this report at https://www.wiseguyreports.com/enquiry/psoriasis-pipeline-review-h1-2016-psoriasis-pipeline-review-h1-2016 .
- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
- The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Psoriasis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
P: +44 208 133 9349
M: +1 646 845 9349